OBJECTIVE： To investigate the clinical characteristics and rules of allergic reaction caused by anti-copper treatment with Sodium dimercaptoproane sulfonate （DMPS） injection， and to provide reference for diagnosis， treatment and monitoring of drug-induced allergic reaction. METHODS： By using retrospective analysis， allergic reaction reports of DMPS injection were selected from our hospital during Jan. 2013-Dec. 2015 were analyzed statistically. RESULTS： A total of 131 cases of allergic reaction were reported. The average age of the patients was （23.26±9.63） years old， mainly concentrated on 10-39 years old （87.79％）. Allergic reaction mainly occurred in the first and second courses of treatment， accounting for 71.76％. For systems-organs involved， skin and its appendages disorders had the highest proportion （85.90％）， being mainly the lesion of limbs （27.45％） and body （22.22％） involved； followed by systemic damage （12.33％）. Clinical manifestations of systemic impairment were mainly fever， with rash or itching at the same time frequently. 131 patients had good outcome after treatment. The symptoms of 115 patients （87.79％） disappeared in 7 d. Serious cases accounted for 25.19％. The proportion of drug allergy history， the rate of anti-copper treatment failure with allergy prevention or desensitization therapy， and symptom duration in patients with severe ADR were higher or longer than that in general ADR cases， the difference was statistically significant（P＜0.05）. CONCLUSIONS： The allergic reaction of DMPS injection increased the difficulty of anti-copper treatment. ADR monitoring should be strengthened in the process of using DMPS， specially for the history of allergies and the first， second treatment courses of patients.